骨质疏松性椎体骨折的病理生理、流行病学及治疗反应新见解
本文为叙述性小型综述,检索2020年以来PubMed上关于人类椎体骨折的研究,概述内分泌疾病中椎体骨折风险及药物治疗新证据。结论指出内分泌科医生应意识到内分泌疾病患者骨质疏松性椎体骨折可能性高,现有获批治疗可大幅减少骨折发生,但近期随机对照试验多聚焦于骨折本身的高级侵入性治疗。
要点
- 内分泌疾病患者骨质疏松性椎体骨折可能性高,内分泌科医生应有所意识。
- 获批的骨质疏松治疗能大幅降低椎体骨折发生率。
- 近期或进行中的椎体骨折随机对照试验多聚焦于骨折本身的先进侵入性治疗。
核心结论
- 内分泌科医生应意识到内分泌疾病患者骨质疏松性椎体骨折的可能性高。
- 获批的治疗能大幅降低骨质疏松患者的椎体骨折发生率。
- 近期或进行中的椎体骨折随机对照试验绝大多数聚焦于骨折本身的高级侵入性治疗。
研究设计与样本
- 叙述性小型综述,于2022年5月23日检索PubMed中关于人类椎体骨折的研究,限2020年及以后发表的英文全文,共获得3457条文献,并补充较早文献以提供背景。
主要发现
- 研究涉及甲状腺功能亢进、甲状旁腺功能亢进、肢端肥大症、库欣综合征、原发性醛固酮增多症和糖尿病的椎体骨折风险。
- 药物治疗方面,识别出关于罗莫索单抗和每周特立帕肽的新研究或分析。
- 多项研究(包括近期管线中的研究)为椎体成形术或后凸成形术的干预研究,包括联合干细胞或药物。
临床怎么用
- 作者认为内分泌科医生应意识到内分泌疾病患者骨质疏松性椎体骨折的可能性高。
- 作者指出获批治疗能大幅降低骨质疏松患者的椎体骨折发生率,但近期或进行中的随机对照试验多聚焦于骨折本身的先进侵入性治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Vertebral fractures (VFs) make up an important but challenging group of fractures often caused by osteoporosis. Osteoporotic fractures pose unique diagnostic challenges in generally requiring imaging for diagnosis. The objective of this narrative mini-review is to provide an overview of these recent advances in our knowledge of VF pathophysiology and epidemiology with particular focus on endocrine diseases, prevention, and treatment. EVIDENCE ACQUISITION: We searched PubMed on May 23, 2022, for studies of VFs in humans. Results were limited to papers available as full-text publications in English, published from 2020 and onward. This yielded 3457 citations. This was supplemented by earlier publications selected to add context to the recent findings. EVIDENCE SYNTHESIS: Studies addressed VF risk in hyperthyreosis, hyperparathyroidism, acromegaly, Cushing syndrome, primary aldosteronism, and diabetes. For pharmaceutical treatment, new studies or analyses were identified for romosozumab and for weekly teriparatide. Several studies, including studies in the immediate pipeline, were intervention studies with vertebroplasty or kyphoplasty, including combination with stem cells or pharmaceuticals. CONCLUSIONS: Endocrinologists should be aware of the high likelihood of osteoporotic VFs in patients with endocrine diseases. Though licensed treatments are able to substantially reduce the occurrence of VFs in patients with osteoporosis, the vast majority of recent or ongoing randomized controlled trials in the VF area focus on advanced invasive therapy of the fracture itself.
引用
- Skjødt MK, Abrahamsen B. New Insights in the Pathophysiology, Epidemiology, and Response to Treatment of Osteoporotic Vertebral Fractures. J Clin Endocrinol Metab. 2023. PMID: 37186550. doi:10.1210/clinem/dgad256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。